Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $14.00.

KLRS has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Chardan Capital assumed coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective for the company. Finally, Citizens Jmp began coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 target price on the stock.

Kalaris Therapeutics Price Performance

NASDAQ KLRS opened at $8.27 on Wednesday. The stock has a market capitalization of $154.65 million, a P/E ratio of -2.19 and a beta of -0.09. The firm’s 50-day moving average is $9.10 and its two-hundred day moving average is $6.27. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $12.90.

Insider Activity

In other Kalaris Therapeutics news, Director Srinivas Akkaraju acquired 479,847 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average price of $10.42 per share, for a total transaction of $5,000,005.74. Following the completion of the acquisition, the director owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. This trade represents a 31.99% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 74.99% of the company’s stock.

Hedge Funds Weigh In On Kalaris Therapeutics

Several institutional investors have recently modified their holdings of KLRS. Goldman Sachs Group Inc. grew its stake in Kalaris Therapeutics by 52.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 34,303 shares of the company’s stock worth $290,000 after purchasing an additional 11,838 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Kalaris Therapeutics by 28.0% in the 4th quarter. Geode Capital Management LLC now owns 82,647 shares of the company’s stock valued at $698,000 after buying an additional 18,096 shares during the period. Woodline Partners LP purchased a new position in shares of Kalaris Therapeutics in the 3rd quarter valued at about $1,394,000. Bridgeway Capital Management LLC acquired a new position in shares of Kalaris Therapeutics during the third quarter worth about $130,000. Finally, Barclays PLC purchased a new stake in shares of Kalaris Therapeutics during the fourth quarter worth approximately $51,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.